{"success":true,"data":{"pressRelease":{"id":"83680","rtpr_id":"nGNX1zDDkj","ticker":"ERAS","exchange":"NASDAQ","all_tickers":["ERAS"],"title":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS","author":"Globe Newswire","published_at":"2026-07-08T18:17:46.100Z","article_body":"SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS)\nfaces a securities class action after the stock tanked $9.25 (-48%) on news\nthat Revolution Medicines (RevMed) accused Erasca of patent infringement\nconcerning Erasca’s pan-RAS molecular glue targeting solid tumors\n(ERAS-0015) and that a patient died one month after receiving ERAS-0015.\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nErasca common stock between January 14, 2025 and April 26, 2026.\n\nNational shareholder rights law firm Hagens Berman is continuing its\ninvestigation into legal claims that Erasca violated the federal securities\nlaws and urges Erasca investors who suffered significant losses to contact the\nfirm now to discuss their rights.\n(https://www.globenewswire.com/Tracker?data=IMJZqJ2ZqqH7npKhY4ws5GC--P8zByvHckUajVgXAQdhSvpargnvaWtjfkHf5aqIhBjcwuo8dHe2S1lULdpilGMb9IEJK6UVNNa7LGzXQ_CCH4jlYfQ9RPwGsrSP9EnUr-3BXwkCys2qNaDnYS5FnOrHfcrF6J36_6fX2vhUcr4=)\n\nClass Period: Jan. 14, 2025 – Apr. 26, 2026\nLead Plaintiff Deadline: Aug. 10, 2026\nVisit: www.hbsslaw.com/investor-fraud/eras \nContact the Firm Now: ERAS@hbsslaw.com \n                                        844-916-0895\n\nErasca, Inc. (ERAS) Securities Class Action:\n\nPrecision oncology company Erasca’s ERAS-0015 is the company’s\ninvestigational, oral, potentially “best-in-class” pan-RAS molecular glue\nunder development to treat RAS-mutant solid tumors, including pancreatic\nductal adenocarcinoma.\n\nThe complaint alleges that Erasca favorably compared the equivalence of its\nERAS-0015 40 milligram dose cohort to RevMed’s RMC-6236 400 milligram dose\ncohort. In addition, as recently as March 12, 2026, Erasca allegedly assured\ninvestors of its ERAS-0015 intellectual property protection, and touted that\nits ERAS-0015 has “in-licensed one patent family from Joyo” that\n“includes one issued US patent, one pending US non-provisional patent\napplication, one issued foreign patent, and thirteen pending foreign patent\napplications.”\n\nThe complaint alleges that Erasca misled the market because, unknown to\ninvestors, comparisons of ERAS-0015 to RMC-6236 were improper, exposed the\ncompany to intellectual property disputes, and as a result the company’s\nproffers about ERAS-0015 lacked a reasonable basis.\n\nThe truth allegedly emerged on April 27, 2026. That day, Erasca disclosed two\nimportant matters concerning the ERAS-0015 “best-in-class” narrative.\n\nFirst, before the market opened, Erasca disclosed that it received a letter\nfrom RevMed’s legal counsel challenging the validity of Erasca’s\nintellectual property claims. RevMed contends Erasca obtained RevMed’s trade\nsecrets through third-party misappropriation and deceptively compared the\ncompeting therapies.\n\nSecond, after the market closed, the company revealed that a patient being\ntreated with ERAS-0015 suffered an adverse event, presented to the ER a month\nafter receiving the treatment, and then died.\n\nThe market swiftly reacted to these disclosures, sending the price of Erasca\nshares down $9.25 (-48%) the next day and wiping out over $2.8 billion of\nErasca’s market capitalization.\n\n“We’re investigating whether Erasca may have intentionally misled\ninvestors about ERAS-0015’s safety profile and about a potential moat in its\nparticular, highly competitive cancer treatment space,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=sqcEJAXygP4WK9Gl-WtRxwNf38D6PtjvHbpnQPMGDMyQLpVMltE2qlm5Vs9YtQ1BQs5s8KL10MmvP5F8NaMg7PXKzMXE6z5sdyBrjc4lWBrDwo8XkHX2d5DM2q6wVeCT),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Erasca and have substantial losses, or have knowledge that\nmay assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=a4rBPpxCJbWsgL0bnPsy4v6yBbk-jWf7UTavRwbvjvpjucGUuHQRbusJ-FdBQUVxzWhWznmbrXR-3w1TKpq9briImYETl9SZiVermuNZcGd8DxBSrslfK45BGHzNzB1G)\n»\n\nIf you’d like more information and answers to other frequently asked\nquestions about the Erasca case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=mj5KHDtvMFQEui9yNGZc6XxjdeutFIhIsoQvOrO5qzqz2EFy32WB5jRTdu9Z4LF7cl2usJFv-rQ7K3e1uYNZT_fsLDKnapjL_vTFKUfhR3wib-uVoCXHh8Hzgi9S0y14UToaIu7tusZwympJjN6nIQ==)\n»\n(https://www.globenewswire.com/Tracker?data=5tGwiEwMMuuapgheArHMIoPs2FTVJXnJXCLmeHK0Lv_4y1UPspFWaYVjXab8t95GQJsp3i6K3Z8a_BMxl5Fdcds-xfhYPqjreZx4D_S77tRkO9megLv3jzKaMKi_Mnq44qKBXY6OnOrC6E2EWD7ltA==)\n\nWhistleblowers: Persons with non-public information regarding Erasca should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email ERAS@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=pQVnPhU9J2GnXhDnEy1OeKmS1rFhTzqlcWEuqn_-PvRJuZZXYAye0tvXHJz8kESW1GUdT9BUyPVhzpvMUXy2xfAgo5cznpahy-TNESWhiI0=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=E_xu-9SwqkKt00YW-tc-kJIbpJ16yOqoEk5zcPuR5Yf-ghrv9DHmAUvacOVrmfPE1e2wyS6Fy0tKryV2-BaJlQ==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact:\nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1zDDkj","title":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS","author":"Globe Newswire","ticker":"ERAS","created":"2026-07-08T18:17:46.100Z","tickers":["ERAS"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS)\nfaces a securities class action after the stock tanked $9.25 (-48%) on news\nthat Revolution Medicines (RevMed) accused Erasca of patent infringement\nconcerning Erasca’s pan-RAS molecular glue targeting solid tumors\n(ERAS-0015) and that a patient died one month after receiving ERAS-0015.\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nErasca common stock between January 14, 2025 and April 26, 2026.\n\nNational shareholder rights law firm Hagens Berman is continuing its\ninvestigation into legal claims that Erasca violated the federal securities\nlaws and urges Erasca investors who suffered significant losses to contact the\nfirm now to discuss their rights.\n(https://www.globenewswire.com/Tracker?data=IMJZqJ2ZqqH7npKhY4ws5GC--P8zByvHckUajVgXAQdhSvpargnvaWtjfkHf5aqIhBjcwuo8dHe2S1lULdpilGMb9IEJK6UVNNa7LGzXQ_CCH4jlYfQ9RPwGsrSP9EnUr-3BXwkCys2qNaDnYS5FnOrHfcrF6J36_6fX2vhUcr4=)\n\nClass Period: Jan. 14, 2025 – Apr. 26, 2026\nLead Plaintiff Deadline: Aug. 10, 2026\nVisit: www.hbsslaw.com/investor-fraud/eras \nContact the Firm Now: ERAS@hbsslaw.com \n                                        844-916-0895\n\nErasca, Inc. (ERAS) Securities Class Action:\n\nPrecision oncology company Erasca’s ERAS-0015 is the company’s\ninvestigational, oral, potentially “best-in-class” pan-RAS molecular glue\nunder development to treat RAS-mutant solid tumors, including pancreatic\nductal adenocarcinoma.\n\nThe complaint alleges that Erasca favorably compared the equivalence of its\nERAS-0015 40 milligram dose cohort to RevMed’s RMC-6236 400 milligram dose\ncohort. In addition, as recently as March 12, 2026, Erasca allegedly assured\ninvestors of its ERAS-0015 intellectual property protection, and touted that\nits ERAS-0015 has “in-licensed one patent family from Joyo” that\n“includes one issued US patent, one pending US non-provisional patent\napplication, one issued foreign patent, and thirteen pending foreign patent\napplications.”\n\nThe complaint alleges that Erasca misled the market because, unknown to\ninvestors, comparisons of ERAS-0015 to RMC-6236 were improper, exposed the\ncompany to intellectual property disputes, and as a result the company’s\nproffers about ERAS-0015 lacked a reasonable basis.\n\nThe truth allegedly emerged on April 27, 2026. That day, Erasca disclosed two\nimportant matters concerning the ERAS-0015 “best-in-class” narrative.\n\nFirst, before the market opened, Erasca disclosed that it received a letter\nfrom RevMed’s legal counsel challenging the validity of Erasca’s\nintellectual property claims. RevMed contends Erasca obtained RevMed’s trade\nsecrets through third-party misappropriation and deceptively compared the\ncompeting therapies.\n\nSecond, after the market closed, the company revealed that a patient being\ntreated with ERAS-0015 suffered an adverse event, presented to the ER a month\nafter receiving the treatment, and then died.\n\nThe market swiftly reacted to these disclosures, sending the price of Erasca\nshares down $9.25 (-48%) the next day and wiping out over $2.8 billion of\nErasca’s market capitalization.\n\n“We’re investigating whether Erasca may have intentionally misled\ninvestors about ERAS-0015’s safety profile and about a potential moat in its\nparticular, highly competitive cancer treatment space,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=sqcEJAXygP4WK9Gl-WtRxwNf38D6PtjvHbpnQPMGDMyQLpVMltE2qlm5Vs9YtQ1BQs5s8KL10MmvP5F8NaMg7PXKzMXE6z5sdyBrjc4lWBrDwo8XkHX2d5DM2q6wVeCT),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Erasca and have substantial losses, or have knowledge that\nmay assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=a4rBPpxCJbWsgL0bnPsy4v6yBbk-jWf7UTavRwbvjvpjucGUuHQRbusJ-FdBQUVxzWhWznmbrXR-3w1TKpq9briImYETl9SZiVermuNZcGd8DxBSrslfK45BGHzNzB1G)\n»\n\nIf you’d like more information and answers to other frequently asked\nquestions about the Erasca case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=mj5KHDtvMFQEui9yNGZc6XxjdeutFIhIsoQvOrO5qzqz2EFy32WB5jRTdu9Z4LF7cl2usJFv-rQ7K3e1uYNZT_fsLDKnapjL_vTFKUfhR3wib-uVoCXHh8Hzgi9S0y14UToaIu7tusZwympJjN6nIQ==)\n»\n(https://www.globenewswire.com/Tracker?data=5tGwiEwMMuuapgheArHMIoPs2FTVJXnJXCLmeHK0Lv_4y1UPspFWaYVjXab8t95GQJsp3i6K3Z8a_BMxl5Fdcds-xfhYPqjreZx4D_S77tRkO9megLv3jzKaMKi_Mnq44qKBXY6OnOrC6E2EWD7ltA==)\n\nWhistleblowers: Persons with non-public information regarding Erasca should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email ERAS@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=pQVnPhU9J2GnXhDnEy1OeKmS1rFhTzqlcWEuqn_-PvRJuZZXYAye0tvXHJz8kESW1GUdT9BUyPVhzpvMUXy2xfAgo5cznpahy-TNESWhiI0=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=E_xu-9SwqkKt00YW-tc-kJIbpJ16yOqoEk5zcPuR5Yf-ghrv9DHmAUvacOVrmfPE1e2wyS6Fy0tKryV2-BaJlQ==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact:\nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-08T18:17:46.196062678Z","server_sent_at_ms":1783534666196},"received_at":"2026-07-08T18:17:46.262Z","source_url":null},"analysis":{"id":"72740","press_release_id":"83680","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman issued a shareholder-solicitation notice naming Erasca, alleging securities law violations related to its ERAS-0015 drug candidate.\n\nThe firm references prior disclosures involving a patient death and intellectual property disputes with Revolution Medicines that reportedly triggered a 48% stock decline.\n\nInvestors who purchased shares between January 14, 2025 and April 26, 2026 are urged to contact the firm before the August 10 lead plaintiff deadline.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"market_cap_loss":"$2.8 billion","stock_drop_amount":"$9.25","stock_drop_percent":"-48%"}},"quotedText":"","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":["ERAS-0015","RMC-6236"],"companies":[{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Erasca, Inc.","ticker":"ERAS"},{"name":"Revolution Medicines","relationship":"competitor"}],"dollarAmounts":[{"amount":"$2.8 billion","context":"Erasca market capitalization loss"},{"amount":"$9.25","context":"share price drop"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Hagens Berman. No new disclosure from the issuer; no certified class or settlement announced. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ERAS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a shareholder-solicitation notice naming Erasca, alleging securities law violations related to its ERAS-0015 drug candidate.\n\nThe firm references prior disclosures involving a patient death and intellectual property disputes with Revolution Medicines that reportedly triggered a 48% stock decline.\n\nInvestors who purchased shares between January 14, 2025 and April 26, 2026 are urged to contact the firm before the August 10 lead plaintiff deadline.","key_figures":{"customDimensions":{"market_cap_loss":"$2.8 billion","stock_drop_amount":"$9.25","stock_drop_percent":"-48%"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":["ERAS-0015","RMC-6236"],"companies":[{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Erasca, Inc.","ticker":"ERAS"},{"name":"Revolution Medicines","relationship":"competitor"}],"dollarAmounts":[{"amount":"$2.8 billion","context":"Erasca market capitalization loss"},{"amount":"$9.25","context":"share price drop"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-08T18:19:20.701Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":94426,"modelName":"george-droid-qwen-72b"}}